Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
In cancer trials or any life threatening trial those not receiving trial drug would receive a standard of care medication. The problem with OM is there is not yet a good standard of care option. I do hope in the phase3 design there will be an allowance for patients to switch to B.
well ion that case i consider the trial inhumane. all imo
imo we should have had an update on this. just more finagling.
Antibiotic of last resort - gone.
Scientists attending a recent meeting of the American Society for Microbiology reported they had uncovered a highly disturbing trend. They revealed that bacteria containing a gene known as mcr-1 – which confers resistance to the antibiotic colistin – had spread round the world at an alarming rate since its original discovery 18 months earlier. In one area of China, it was found that 25% of hospital patients now carried the gene.
Colistin is known as the “antibiotic of last resort”. In many parts of the world doctors have turned to its use because patients were no longer responding to any other antimicrobial agent. Now resistance to its use is spreading across the globe.
https://www.theguardian.com/society/2017/oct/08/world-faces-antibiotic-apocalypse-says-chief-medical-officer
Dartmouth (The Big Green) says Phase III which is not correct.
clinicaltrials.gov still showing Mary Crowley (Dallas Tx) for Phase 2A.
I'm explaining the financial economics behind the value of IPIX shares and an equivalent call option. You're giving an analogy that is misleading but more folks can relate to.
An equity investment is not really like a lottery ticket but people do often view them that way.
FWIW K-OC is no longer listed on Mary Crowley's website. Perhaps enrollment (cohort 1) is completed? This used to be the link.
https://www.marycrowley.org/clinical-trials/17-02/
The trial is still active at the Dartmouth location.
http://cancer.dartmouth.edu/patients/clinical_trial/F17098/
From October 1 to December 31.
Are we going to be blessed by one of your price predictions anytime soon? Maybe "Expect $10 by or before March 2018".
Or "Expect the share price to triple by or before 2018"
Still not sure what the difference is between "by" and "before".
"Our company has been under attack by criminals whose goal would be to bankrupt the company and have everyone lose their investment."
"IMO abusive naked short selling needs to be stopped and I intend to do all that I can to see that happen while educating investors many of whom don't have a clue as to what is happening."
I'll admit to not having a clue, so educate me. What evidence is there to show that Innovation Pharmaceuticals Inc. has been under attack by criminals whose goal it is to bankrupt the company through naked short selling?
sox04 when is the 4th quarter for IPIX? tia
Leo had reported they were fielding calls from BP, imo Leo's phone soon to be ringing off the hook. With B Leo's clearly in the deal drivers seat.
Recent Psoriasis Deals
1. Allergan in $640M Vitae buyout deal as it further expands dermatology pipeline
"Allergan buys into the Fort Washington, PA-based biotech’s dermatology pipeline that includes VTP-43742, a midstage, first-in-class, orally active ROR?t (retinoic acid receptor-related orphan receptor gamma) inhibitor for the potential treatment of psoriasis, as well as other autoimmune disorders."
http://www.fiercebiotech.com/biotech/allergan-640m-vitae-buyout-deal-as-it-further-expands-dermatology-pipeline
"The compound recently completed a Phase 2 proof-of-concept multiple ascending dose trial in patients with moderate to severe psoriasis."
https://www.allergan.com/news/news/thomson-reuters/allergan-to-acquire-vitae-pharmaceuticals-adding-i
2. Fumarate makes weight as Xenoport, Dr. Reddy's ink potential $490M deal
"The terms call for $47.5 million up front and another $2.5 million related to the transfer of certain clinical trial materials to Dr. Reddy's. Xenoport will be eligible for as much as $190 million if regulatory milestones are met, which could happen over a period of several years, the companies said. Up to $250 million more may come if commercial goals are hit, and royalties as high as the midteens are included for U.S. sales."
http://www.bioworld.com/content/fumarate-makes-weight-xenoport-dr-reddys-ink-potential-490m-deal-0
"Shares of Santa Clara, CA-based XenoPort were down 25 percent by midmorning Tuesday after the company announced positive preliminary results from a Phase 2 clinical trial of its oral psoriasis drug.
Although the biotech said it expects to begin Phase 3 trials of its drug, XP23829, in 2016, a high rate of gastrointestinal side effects may impede its efforts. XenoPort’s shares had initially been up 19 percent earlier Tuesday morning."
https://www.dddmag.com/news/2015/09/xenoport-shares-dive-after-psoriasis-drug-study-results
3. Purdue Strikes $790 Million Exicure Deal to Diversify
"Purdue Pharma LP has struck a deal with Exicure Inc. to buy the rights to an experimental psoriasis treatment for as much as $790 million, the latest in a string of moves to diversify away from opioid pain drugs, the backbone of the company’s business."
https://www.bloomberg.com/news/articles/2016-12-12/purdue-strikes-790-million-exicure-deal-to-diversify-from-pain
4. AbbVie hands over $595M upfront to partner with Boehringer on PhIII psoriasis drug
"AbbVie ($ABBV) is handing over $595 million in an upfront payment to partner with Boehringer Ingelheim on its late-stage psoriasis drug, the anti-IL-23 BI 655066."
http://www.fiercebiotech.com/partnering/abbvie-hands-over-595m-upfront-to-partner-boehringer-on-phiii-psoriasis-drug
Recent IBD Deals
1. Johnson & Johnson commits $990M to land Protagonist’s oral Crohn’s drug (preclinical)
"Johnson & Johnson has landed rights to Protagonist Therapeutics’ preclinical Crohn’s disease asset PTG-200. The deal gives J&J a stake in an oral interleukin-23 (IL-23) receptor antagonist in return for $50 million upfront and up to $940 million in milestones."
"The asset is due to enter the clinic this year. Protagonist will run and fund the trial with J&J taking over—and covering 80% of the costs—once it advances to phase 2. Beyond this, a series of major paydays await Protagonist. J&J will pay Protagonist $125 million if it moves the drug into phase 2b and a further $200 million if it sticks with the asset after getting a look at data from the trial. The rest of the cash is tied to regulatory and sales milestones."
http://www.fiercebiotech.com/biotech/j-j-commits-990m-to-land-protagonist-s-oral-crohn-s-drug
2. Celgene Completes Acquisition of Receptos, Advancing Leadership in Immune-Inflammatory Diseases
"Celgene Corporation (CELG) today announced it has closed its acquisition of Receptos, Inc. Receptos stockholders received $232.00 per share in cash, for a total of approximately $7.2 billion, net of cash acquired."
http://www.fiercepharma.com/pharma/celgene-completes-acquisition-of-receptos-advancing-leadership-immune-inflammatory-diseases
3. Celgene enters deal potentially worth over $2.5 billion for Nogra Pharma's Crohn's disease drug
"Celgene announced a global licensing deal Thursday potentially valued at more than $2.5 billion to develop and market Nogra Pharma's experimental drug GED-0301 for moderate-to-severe Crohn's disease and other indications."
https://www.firstwordpharma.com/node/1205296?tsid=1
4. Gilead swoops down on Galapagos JAK1 candidate filgotinib in $2.075B deal
"Gilead Sciences Inc., is stepping in where Abbvie Inc. stepped out, laying down a whopping $725 million, with up to $1.35 billion more to come in milestones, for rights to Galapagos NV's Janus kinase 1 (JAK1)-selective inhibitor filgotinib (GLPG0634)."
http://www.bioworld.com/content/gilead-swoops-down-galapagos-jak1-candidate-filgotinib-2075b-deal
5. Salix Expands in GI Drugs and Beyond with $2.6B Santarus Acquisition
"Salix Pharmaceuticals said it will acquire Santarus for about $2.6 billion, in an all-cash deal that expands the buyer’s gastrointestinal (GI) drug portfolio and extends its product offerings into primary care and diabetes."
http://www.genengnews.com/gen-news-highlights/salix-expands-in-gi-drugs-and-beyond-with-2-6b-santarus-acquisition/81249089
1/13/2016 - $0.95 (low)
5/2/2016 - $1.87 (high)
2016 Potential Catalyst
1. P: Phase 2a top-line data - Q2
P Phase 2a Timelines
3/17/2016 - Last patient visit
3/17/2016 - Run-up started with +29% on ~900K volume ($1.56 closing price)
3/18/2016 - Run-up continued with +14% on ~600K volume ($1.78 closing price)
5/24/2016 - Top-line result
What tax-loss selling?
11/01/2016 - $1.16
12/30/2016 - $1.16
5/10/2017 - $0.63 (low)
2017 high - ?
2017 Potential Catalysts
1. B-OM: top-line data - October/November
2. P: Phase 2b top-line data - Decemer/January
3. K-OC: interim data - Q4
Who else you think should fund IPIX and what will they get in return of that funding?
Very good question. Any new ideas?
Nice explanation, but you are over thinking IPIX's situation.
A straight forward analogy most here will understand is more appropriate.
IPIX is like a scratch off lottery ticket where we have matched 5 of the first seven numbers. We have not really won any money, but the 6th number is slowly becoming more visible; and our prospects are looking better. If the sixth number matches we will win many dollars and if the 7th number matches we win the lottery.
Unfortunately if the numbers do not match, investors lose the price of their ticket.
Good luck to all
Farrell
Believe the FACTS rather than the FUD (Fear, Uncertainty and Doubts)
The FACTS follow direct from Innovation Pharmaceuticals
The Company believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. The Company’s psoriasis drug candidate Prurisol completed a Phase 2 trial and the Company more recently launched a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. The Company’s anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and the Company has commenced a Phase 2 study. In the laboratory, Kevetrin has been shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Brilacidin, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. The Company is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of oral mucositis in patients with head and neck cancer; interim results have shown a marked reduction in the incidence of severe oral mucositis (WHO Grade ≥ 3). The Company’s lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (“superbugs”). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD). The Company has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Company website at www.IPharmInc.com.
Good luck and GOD bless,
George
Yes, credibility is a (overdone) issue with IPIX, unfortunately. A partnership wipes that out. First, it provides hard cash. Second, it is an agency signal that an experienced commercial third party finds value in the company's pipeline. The market already deems some expected value in the pipeline, but "only" $100MM at the moment. (Though $100MM is nothing to sneeze at.)
Payday deposit for more myself. Looking forward to data.
#innovation Pharmaceuticals Inc. Going on the map.
$IPIX
Yes. Applying the Law of One Price here: the market is saying that the value of an IPIX call option of strike price = $0 and infinitely long expiry would have a FV of around 70 cents. This is true for any company that has little salvage value, ie owns hard assets of little liquidation value. Such a call option would not only have the same price but the same risk as a share of stock. And of course they would; otherwise the prices would not be the same. (Scottsmith are you getting the point?)
This is a high finance concept and not commonly understood by most retail investors. It is not necessary to understand this for IPIX
because no one writes IPIX options, which is just as well because you should just buy the stock instead. Everyone who understands this so far would also understand that if someone did sell IPIX options they would have to sell them for less than $.70. The share price is the effective ceiling. (Go ahead and think of an IPIX option contact where you'd be willing to pay more than $.70 right now.)
So is $.70 "cheap"? Yes, to me this is a cheap infinite option. But that is subjective.
Absolutely. I'd have cut my loss and run if I didn't believe them. Plus, I like the fact they didn't bet the farm on one drug. It's not like they are a pfizer with oodles of cash sitting around. They have always pulled cash on an as needed basis from what I can see.
There has been a ph1 and two ph2's for brilacidin ABSSSI putting the drug in hundreds of patients. The second ph2b tweaked the dosage and that alleviated the safety issues from the ph2a.
Also, the FDA wouldn't have given the go ahead for the trial if they had serious safety concerns.
Take a look at my interview with Dr Bertolino shortly after he came on board.
Interview With New Cellceutix President Dr A Bertolino
https://seekingalpha.com/article/3988240-interview-new-cellceutix-president-dr-bertolino
Share price predictions aren't easy other than to say with good results it should go up. A partnership should make it go up quite a bit. ;)
One of the best things a partnership will do for this company is bring validation. The various false hit pieces have dragged the name through the mud.
I bought a bit more yesterday since I like the fact we'll be getting topline on brilacidin OM soon.
Karin, Brilacidin for ABSSSI seems to have dropped off the screen, do you still accept the IPIX rationale that there will be no FDA3 because of the 30 mil price tag? The more I think about it (and review some high quality posts)the more I have accepted the contention that FDA has safety concerns with systemic uses of Brilacidin.
It depends on results of OM and P.
I get what your saying but it will be pretty pathetic if we're still around a buck or just over at year end
I am pretty sure we will at least be back over 1.00. I will leave it at that because I don't think we will see our biggest move until a deal is inked.
Yes, I am referring to the two indications Oral Muscositis application and the UPS application.
Share price projections for the end of year, anyone care to take a stab? Depends on a lot of variables I know!
I take it you are only talking about Brilacidin for the Oral Muscositis application (and possibly the UPS application when used as an enema or w/ a gel/foam formulation. For the ABSSSI and Upper Colitis/expected Crohn's Disease applications and other IBD apps it would have to be ingested and systematic buildup considered. Anyway, that is my interpretation of it. Could be a bit off. If it is, please anyone with positive info correct me.
The amazing effects from Brilacidin is, that the body isn't even subjected to in gestation of the formula for the amazing results it has shown. Wouldn't that be a consideration for fast track?
Thanks cybermich. IPIX answers all the arguments when they deliver. By that I mean finding a partner giving credibility to the Company and it's science.If that happens we get stability and a future.
I am confident of such as well...concerning the law of one price the 'correction' will come as the 'exploits of brilacidin concerning efficacy' will become more clear..this will give more equilibrium to the supposed decay of share price versus what the company actually has in terms of its arsenal and what BP may be interested in/market approval - i mean as you have stated we are talking about a very inexpensive option...as far as I can see the strike price for that optio be 71 cents for quite some time giving more strength to the law of one price...which gives more credence to the fact there will be some correction in share price equilibrium once we get results, which are due in 4 weeks where the price will probably and inmo should stay
I think we both made our points
You're describing a patient, vigilant, informed, diversified investor. Always the way to go. Impatient, paranoid, and ignorant is not being an investor. People foolishly find that out the hard way.
About the only thing I'm confident of is it is likely some folks will be buying soon. You never know timing.
The point is that the share price is effectively the "option price" and has no explicit decay. Their analogy is rough, but valid. The finance law of "One Price" is valid. There is a theoretical equivalency at work.
Shorts aren't manipulating ipix at less than one percent of O/S.
I think it's true regardless of the board. It's just rare on most boards
options "expire".. if you "time" it wrong you can lose all of your investment..
knowing what you own takes the "timing" factor out of the equation (when
you "own" the shares..)
imagine the risk in the last couple years in trying to "time" the option price:)
good luck with that...
imo the only way to win this IPIX "game" is to let the science cross the finish line..
the shorts can manipulate the short term.. but they are powerless if/when the
science matures.
I know I am stating the obvious.. (to most here <wink>)
good luck to all real IPIX shareholders
I expect a run-up to B-OM result after the last patient visit, which should be by the end of this month. Same for P, which should be by the end of this year. If you look at the historical data, there was a ~100% run-up prior to P last year and ~50% run-up prior to B-UP this year.
Thanks for posting the correct short sales/interest info and link to FINRA.
FINRA Short Interest of IPIX
Settlement Date: 9/15/2017
Current Short: 1,214,089
Previous Short: 1,220,108
Change: -6,019 (-0.49%)
Average Daily Volume: 215,861
Days to Cover: 5.62
0.92% of the outstanding shares were short.
http://otce.finra.org/ESI
According to the SEC, only 11,557 shares (0.009% of the OS) were failure-to-deliver as of August 31.
20170831|45782D100|IPIX|11557|INNOVATION PHARMACEU|0.70
https://www.sec.gov/data/foiadocsfailsdatahtm
If the call option is .70, you still lose 100% of the option purchase price, .70. If the option is for 2.50, then you need 3.20 plus fees to make any money. Anything lower is a loss. Anything below 2.50 plus fees is a 100% loss.
If you buy a share you buy the share price. You could lose 100 percent. If you buy a call option you don't have to purchase. You can simply lose the premium if you want. Risk is less.
not on any board that ive seen
Well stated. I was reacting to the more general “option” statement.
You have no obligation to buy anything further with either.
Followers
|
976
|
Posters
|
|
Posts (Today)
|
3
|
Posts (Total)
|
402948
|
Created
|
05/10/08
|
Type
|
Free
|
Moderators zandant Minnesinger sunspotter snayeman loanranger frenchbroad |
Innovation Pharmaceuticals Inc. (IPIX)
$IPIX NEWS - http://ipharminc.com/press-release
SEC Filings https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
From the most recent 10-K:
There are doubts about our ability to continue as a going concern.
We have generated revenue of $0 and $18,000 for the fiscal years ended June 30, 2023 and 2022, respectively and have an accumulated deficit of $125.3 million through June 30, 2023. These factors raise substantial doubt about our ability to continue as a going concern.
We need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms, which could prevent us from fully implementing our business, operating and development plans.
We currently have an approximate $1.0 million cash balance as of the date of this filing, but that is insufficient to complete the development and commercialization of any of our proposed products. We expect to incur costs of approximately $1.8 million in the upcoming fiscal year ending June 30, 2024 to operate our business in accordance with our business plans and budgets.
We have limited experience in drug and formulation development, the conduct of clinical trials, and may not be able to successfully develop any drugs.
Development of pharmaceutical products is a risky and time-consuming process subject to a number of factors, many of which are outside of our control. We are subject to regulatory authority permissions and approvals, most importantly the FDA. Our drug candidate(s)/indications are at early and mid-stages of development. Consequently, we can provide no assurance of the successful and timely development of new drugs, and the failure to do so could cause us to cease operations.
We may elect to deregister our common stock under the Exchange Act and suspend our reporting obligations. Such deregistration and suspension would result in less disclosure about us and may negatively affect the liquidity and trading prices of our common stock.
http://www.ipharminc.com/
About Innovation Pharmaceuticals Inc.:
Established in 2007, and headquartered in Wakefield, Massachusetts, Innovation Pharmaceuticals Inc. (formerly Cellceutix Corporation) is a publicly traded biopharmaceutical company dedicated to discovering and advancing innovative medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications.
Through ongoing research and drug development efforts, Innovation is focused on improving the clinical care of patients, as well as growing shareholder value. Our team consists of a diverse and accomplished group of professionals working together toward achieving this common goal.
IPIX CEO - "The Company historically devoted most of its efforts and resources on business development, regulatory matters, and clinical trials. Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully." "In general, we expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials." Source - https://www.sec.gov/ix?doc=/Archives/edgar/data/1355250/000147793223003414/ipix_10q.htm
More information is available at http://www.ipharminc.com.
Management: http://www.ipharminc.com/senior-management/
Scientific Advisors: http://www.ipharminc.com/scientific-advisors/
Clinical Trials: https://clinicaltrials.gov/ct2/results?cond=&term=%22Innovation+Pharmaceuticals%2C+Inc.%22++&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Trials under previous name: https://clinicaltrials.gov/ct2/results?cond=&term=cellceutix&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Product Pipeline: http://www.ipharminc.com/therapeutic-areas/
Recent News and Press Releases:
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/
SEC Filings (CIK:0001355250): https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com
Share Structure: See SEC filing link above for current share structure
Investor Relations:
http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1
Chart: https://stockcharts.com/h-sc/ui?s=IPIX
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |